Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Did We Hear This Biotech’s Last Earnings Call Ever?

Page 2 of 2

My guess is that if $130 without a CVR becomes the final offer, it’ll be hard for Onyx’s board to turn it down, considering it’s a 50% premium on the price before Amgen made its initial offer. The upside from here doesn’t look tempting given the downside risk that a deal won’t go through, however small it may be.

The article Did We Hear This Biotech’s Last Earnings Call Ever? originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool and owns shares of Amazon.com, Apple, Facebook, and Google.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2